- Home
- IMNM
IMNM
Immunome Inc.
as 07-26-2024 4:00pm EST
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BOTHELL |
| Market Cap: | 874.9M | IPO Year: | 2020 |
| Target Price: | $29.75 | AVG Volume (30 days): | 986.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.55 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.13 - $30.96 | Next Earning Date: | 08-07-2024 |
| Revenue: | $12,683,000 | Revenue Growth: | 436.51% |
| Revenue Growth (this year): | -49.03% | Revenue Growth (next year): | -88.58% |
Stock Insider Trading Activity of Immunome Inc. (IMNM)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| BIENAIME JEAN JACQUES | IMNM | Director | May 21 '24 | Buy | $13.57 | 2,000 | $27,139.80 | 9,615 | SEC Form 4 |
| SIEGALL CLAY B | IMNM | President and CEO | May 20 '24 | Buy | $13.91 | 79,566 | $1,106,524.36 | 399,202 | SEC Form 4 |
| SIEGALL CLAY B | IMNM | President and CEO | May 20 '24 | Buy | $13.78 | 20,434 | $281,547.83 | 419,636 | SEC Form 4 |
Latest Immunome Inc. News
IMNM Breaking Stock News: Dive into IMNM Ticker-Specific Updates for Smart Investing
Business Wire
a day ago
Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities
Simply Wall St.
7 days ago
Immunome Insiders Added US$2.67m Of Stock To Their Holdings
Business Wire
a month ago
Immunome Appoints Phil Tsai as Chief Technical Officer
Argus Research
2 months ago
Daily – Vickers Top Buyers & Sellers for 05/22/2024
GuruFocus.com
2 months ago
Insider Buying: Immunome Inc's CEO Acquires 100,000 Shares
MT Newswires
2 months ago
Immunome Insider Bought Shares Worth $1,388,072, According to a Recent SEC Filing
MT Newswires
2 months ago
Immunome Completes Purchase of Antibodies From Atreca
Business Wire
2 months ago
Immunome Announces Completion of Purchase of Assets from Atreca
Compare IMNM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMNM Immunome Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.